38. Stevens-Johnson syndrome Clinical trials / Disease details


Clinical trials : 17 Drugs : 29 - (DrugBank : 9) / Drug target genes : 15 - Drug target pathways : 101

  
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02987257
(ClinicalTrials.gov)
March 15, 202325/11/2016NATIENS: Optimal Management and Mechanisms of SJS/TENNATIENS: A Phase III Randomized Double-Blinded Placebo Controlled Study to Determine the Optimal Management and Mechanisms of Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisStevens-Johnson Syndrome;Toxic Epidermal NecrolysesDrug: Harmonized supportive care;Drug: Cyclosporine 5 mg/kg bid days 0-14;Drug: Etanercept 50 mg sc day 0 and day 3Vanderbilt University Medical CenterUniversity of Ottawa;University of TorontoNot yet recruiting18 YearsN/AAll267Phase 3United States
2NCT05520086
(ClinicalTrials.gov)
November 11, 202222/8/2022Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis.Phase IIa Multicenter Clinical Trial to Determine the Feasibility and Safety of the Use of Adipose-derived Mesenchymal Stem Cells (ASC) in the Treatment of Patients With Cicatricial Conjunctivitis Associated With Lyell's Syndrome, Stevens-Johnson Syndrome and Pemphigoid of the Mucous Membranes With Ocular Involvement.Chronic Conjunctivitis;Stevens-Johnson Syndrome;Lyell Syndrome;PemphigoidDrug: Single Dose;Drug: Double DoseInstituto de Investigación Sanitaria de la Fundación Jiménez DíazEffice Servicios Para la Investigacion S.L.Recruiting18 YearsN/AAll20Phase 1/Phase 2Spain
3EUCTR2021-005486-40-ES
(EUCTR)
22/07/202211/02/2022Clinical Trial to evaluate safety and efficacy of cell therapy in patients with cicatricial conjuntivitisPhase IIa multicenter clinical trial to determine the feasibility and safety of the use of adipose-derived mesenchymal stem cells (ASC) in the treatment of patients with cicatricial conjunctivitis associated with Lyell's syndrome, Stevens-Johnson syndrome and pemphigoid of the mucous membranes with ocular involvement. Cicatricial conjunctivitis associated with Lyell's syndrome, Stevens-Johnson syndrome and mucous membrane pemphigoid with ocular involvement.;Therapeutic area: Diseases [C] - Eye Diseases [C11]Product Name: allogenic mesenchymal stem cell isolated from adipose tissue
INN or Proposed INN: ALLOGENEIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS EXPANDED
Other descriptive name: ALLOGENEIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS EXPANDED
Product Name: allogenic mesenchymal stem cell isolated from adipose tissue
INN or Proposed INN: ALLOGENEIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS EXPANDED
Other descriptive name: ALLOGENEIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS EXPANDED
FUNDACION JIMENEZ DIAZ HEALTH RESEARCH INSTITUTENULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
20Phase 2Spain
4JPRN-jRCTs031210325
01/10/202117/09/2021Etanercept therapy for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) cases of refractory to systemic steroid therapyopen-label, multicenter, single-arm study to evaluate the efficacy and safety of etanercept in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis who were ineffective with systemic steroid therapy stevens-johnson syndrome, toxic epidermal necrosis
stevens-johnson syndrome, toxic epidermal necrosis
Etanercept 50 mg / day is subcutaneously administered on the first day (Day 1). If epithelialization is not complete, administer once on day 8 (Day 8) and day 15 (Day 15) as needed.Abe RiichirouNULLRecruiting>= 20age oldNot applicableBoth10Phase 2Japan
5EUCTR2020-003544-83-FR
(EUCTR)
16/03/202108/01/2021Evaluation de l’efficacité thérapeutique du filgrastim dans les allergies sévères bulleuses aux médicaments s’exprimant sous forme de Lyell et Stevens-Johnson Etude GNETEvaluation de l’efficacité thérapeutique du filgrastim dans les allergies sévères bulleuses aux médicaments s’exprimant sous forme de Lyell et Stevens-Johnson Etude GNET Syndrome de Stevens Johnson (SJS)Syndrome de Lyell (NET)
MedDRA version: 20.1;Level: LLT;Classification code 10042030;Term: Stevens Johnson syndrome;System Organ Class: 100000004858
MedDRA version: 20.0;Classification code 10025166;Term: Lyell syndrome;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Trade Name: ZARZIO
INN or Proposed INN: FILGRASTIM
Hospices Civils de Lyon - Direction de la Recherche CliniqueNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
42Phase 2;Phase 3France
6NCT03585946
(ClinicalTrials.gov)
January 1, 202114/3/2018Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal NecrolysisA Prospective Multicenter Cohort Study Assessing Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal NecrolysisStevens-Johnson Syndrome;Toxic Epidermal Necrolysis;Drug ReactionDrug: Site specific standard of care comparisonMassachusetts General HospitalNULLNot yet recruiting18 YearsN/AAll750NULL
7JPRN-jRCTs061180044
01/06/201712/03/2019Multicenter Open-trial of Steroid pulse therapy for SJS/TENMulticenter Open-trial of Steroid pulse therapy for SJS/TEN - MOSST Study Stevens-Johnson syndrome and Toxic epidermal necrolysis1. infusion of methylprednisolone at 500~1000 mg/d
(0.9% N/S in 3 hour) for 3 consecutive days.
2. Oral predonisolone (0.5 mg/kg/d) was initiated on the
day following the last dose of methylprednisolone, and
prednisolone was subsequently tapered within 2 weeks.
If the ocular involvement score is more than 2, dose of
oral predonisolone (1 mg/kg/d) is recommended.
Morita EishinNULLComplete>= 20age old<= 90age oldBoth20Phase 2Taiwan;Germany;Japan
8NCT05284929
(ClinicalTrials.gov)
May 17, 201710/3/2022Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian PopulationIncreased Frequencies of Certain HLA Class II Alleles DRB1 and DQB1 in PV Patients Compared to Those in Healthy Donors Have Been Reported in Various Populations and Repeatedly Confirmed. Among the Russian Population, no Studies About the Association of PV and HLA Class II Genes Have Been Conducted. Thus, the Purpose of This Study Was to Investigate HLA Class II Alleles and Haplotypes in Russian Patients With Pemphigus Vulgaris.Pemphigus;Bullous Pemphigoid;Stevens-Johnson Syndrome;Toxic Epidermal NecrolysesGenetic: A single blood sample for HLA typingSechenov UniversityPirogov Russian National Research Medical UniversityRecruitingN/AN/AAll120Russian Federation
9NCT03046914
(ClinicalTrials.gov)
February 24, 20166/2/2017HLA-B*5801 Screening to Prevent Allopurinol-induced Severe Cutaneous Adverse ReactionA Prospective Study to Prove the Usefulness of HLA-B*5801 Screening Test for the Prevention of Allopurinol-induced Severe Cutaneous Adverse Reaction in Patient With Chronic Kidney DiseaseStevens-Johnson Syndrome;Kidney Failure, ChronicGenetic: HLA-B*5801 testSeoul National University HospitalMinistry of Food and Drug Safety, KoreaRecruitingN/AN/AAll600N/AKorea, Republic of
10NCT02126020
(ClinicalTrials.gov)
November 201427/4/2014Topical Infliximab in Autoimmune Eyes With KeratoprosthesisTopical Infliximab in Autoimmune Eyes With KeratoprosthesisStevens-Johnson Syndrome;Toxic Epidermal Necrolysis (Lyell) Syndrome;Mucous Membrane PemphigoidDrug: topical infliximabJames Chodosh, MD, MPHMassachusetts Eye and Ear Infirmary;Fonds de recherche en ophtalmologie de l'Université de Montréal (FROUM)Withdrawn18 Years80 YearsAll0Phase 1/Phase 2United States;Canada
11NCT02149732
(ClinicalTrials.gov)
May 201414/5/2014Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet TransplantationAn Investigator-initiated Trial (IIT) on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation in Corneal Limbal Deficiency PatientsLimbal Stem Cell Deficiency;Stevens-johnson Syndrome;Ocular Cicatricial Pemphigoid;Chemical BurnBiological: cultivated oral mucosal epithelial sheet transplantationSeoul National University HospitalMinistry of Health & Welfare, KoreaAvailable16 YearsN/ABothPhase 1/Phase 2Korea, Republic of
12EUCTR2012-003136-23-GB
(EUCTR)
27/11/201216/11/2012Lamotrigine And Borderline Personality Disorder: Investigating Long-Term EffectivenessLamotrigine And Borderline Personality Disorder: Investigating Long-Term Effectiveness - LABILE Borderline Personality Disorder
MedDRA version: 14.1;Level: PT;Classification code 10042033;Term: Stevens-Johnson syndrome;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders
MedDRA version: 14.1;Classification code 10019211;Term: Headache;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 15.0;Level: LLT;Classification code 10028821;Term: Nausea with vomiting;System Organ Class: 100000004856
MedDRA version: 14.1;Classification code 10040913;Term: Skin rash;Classification code 10024264;Term: Lethargy;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 14.1;Classification code 10013649;Term: Drowsiness;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
Trade Name: Lamotrigine - generic product
Product Name: Lamotrigine
Product Code: n/a
INN or Proposed INN: Lamotrigine
Other descriptive name: 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine
Imperial College LondonNULLNot Recruiting Female: yes
Male: yes
252 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yesUnited Kingdom
13NCT01696500
(ClinicalTrials.gov)
October 201220/9/2012Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.Stevens-Johnson Syndrome;Toxic Epidermal NecrolysisDrug: Intravenous immunoglobulinNihon Pharmaceutical Co., LtdNULLCompleted20 YearsN/ABoth10Phase 3Japan
14NCT01582880
(ClinicalTrials.gov)
March 201210/4/2012Use of Cross-linked Donor Corneas as Carriers for the Boston KeratoprosthesisThe Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston KeratoprosthesisChemical Injuries;Unspecified Complication of Corneal Transplant;Autoimmune Diseases;Ocular Cicatricial Pemphigoid;Stevens Johnson Syndrome;Lupus Erythematosus, Systemic;Rheumatoid Arthritis;Other Autoimmune DiseasesDrug: RiboflavinJoseph B. Ciolino, MDNULLCompleted18 YearsN/AAll1Phase 1/Phase 2United States
15NCT01256489
(ClinicalTrials.gov)
December 201019/11/2010Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)Infliximab Therapy to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal NecrolysisStevens-Johnson Syndrome;Corneal BlindnessDrug: InfliximabMassachusetts Eye and Ear InfirmaryNULLWithdrawn18 YearsN/ABoth0Phase 1/Phase 2United States
16NCT02037347
(ClinicalTrials.gov)
October 201013/1/2014Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal NecrolysisPalifermin Treatment of Toxic Epidermal NecrolysisToxic Epidermal Necrolysis;Stevens-Johnson SyndromeDrug: PaliferminBrett KingSwedish Orphan BiovitrumTerminated18 YearsN/AAll1Phase 1/Phase 2United States
17NCT01488396
(ClinicalTrials.gov)
February 20078/11/2010Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry EyeEfficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry EyeStevens-Johnson SyndromeDrug: 0.05%cyclosporin eye dropMahidol UniversityNULLCompleted18 YearsN/ABoth31Phase 4Thailand